Wire · opportunities
FDA Approves Enlicitide, an Oral PCSK9 Inhibitor, for LDL-Lowering
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 July 2026 · Fusion42 review
The FDA has approved enlicitide (Lipfendra), the first oral PCSK9 inhibitor for LDL-lowering, as a once-daily alternative to existing injectable options from Amgen, Novartis, and Sanofi/Regeneron. The approval is based on phase III trial data showing 55–59% LDL reduction versus placebo, with comparable safety to injections.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you sell support tools, patient adherence software, or cost-management platforms into the PCSK9 market, your moat just shifted: oral pills scale faster than injections and will soon attract price-conscious payers who've held these drugs as premium-only. Merck's real win isn't the drug—it's the 14,500-patient outcomes trial that will either bury the other four PCSK9s or force them into combination therapy, turning you into a downstream dependency for whichever one survives.
◆ Coverage
1 source · 16 Jul 2026
◆ Related on Wire
◆ Topics